Because secondary aplastic anemia is a fatal side effect of AML treatment, it is helpful to determine susceptibility to this complication before chemotherapy is ensued. One of the ways that this can be done is by looking for mutations in FA genes that predispose to the development of aplastic anemia. However, for this information to be clinically useful, testing for these genes must be quick, since AML treatment should be commenced immediately. Because secondary aplastic anemia is a fatal side effect of AML treatment, it is helpful to determine susceptibility to this complication before chemotherapy is ensued. One of the ways that this can be done is by looking for mutations in FA genes that predispose to the development of aplastic anemia. However, for this information to be clinically useful, testing for these genes must be quick, since AML treatment should be commenced immediately. This research thus asks, “In AML patients who have undergone chemotherapy, what FA genes are predictive of developing secondary aplastic anemia? To answer this, the experiment will be conducted, with the general objective of suggesting genes that can be tested in order to predict the occurrence of aplastic anemia secondary to chemotherapy.Specific objectives include, 1) comparing FA gene mutations in post-treatment AML patients with or without secondary aplastic anemia, 2) determining predictive values of the various genetic mutations for the occurrence of secondary aplastic anemia, and 3) planning a quick screening test for AML patients before initiation of chemotherapy. Research planThis retrospective study will employ a retrospective design to identify FA genes predictive of secondary aplastic anemia in AML patients. sampling at least 200 adult individuals without FA that has a present or past medical history of AML and subsequent chemotherapy will be the subject of this study. They will be classified into those that had or have acquired secondary anaplastic anemia and to those that have not.
Alter B. P., and Kupfer, G., 2013. Fanconi Anemia. In: Pagon R. A., Bird, T. D., Dolan, C. R., Stephens, K., and Adam, M. P., eds. GeneReviews™ [online]. Seattle (WA): University of Washington, Seattle; 1993-. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1401/
Dans, A. L., Dans, L. F., and Silvestre, M. A., 2008. Painless Evidence-Based Medicine. England: Wiley, p. 50
Emadi, A., and Karp, J. E., 2012. The clinically relevant pharmacogenomics changes in acute myelogenous leukemia. Pharmacogenomics. 13(11), pp. 1257-1269.
Kim, D. H., Han, B., Lee, K., Ahn, T., Son, D. S., Sohn. I., Jung, S. H., Park, K., Jang, J. H., Kim, K., Kim, H. J., Sohn, S. K., Moon, J. H., Kim, J., Huh, N., and Jung, C. W., 2010. Pharmacogenomics-based drug response prediction model for acute myeloid leukemia with normal karyotype. Florida, USA. 5 December 2010. Washington, USA: American Society of Hematology
Mayo Clinic, 2012. Acute Myelogenous Leukemia. [online]. Available at: < http://www.mayoclinic.com/health/acute-myelogenous-leukemia/DS00548>
Meetei, A. R., Levitus, M., Xue, Y., Medhurst, A. L., Zwaan, M., Ling, C., Rooimans, M. A., Bier, P., Hoatlin, M., Pals, G., de Winter, J. P., Wang, W., and Joenje, H., 2004. X-linked inheritance of Fanconi anemia complementation group B. Nature Genetics, 36, pp. 1219-1224.
Online Mendelian Inheritance in Man, 2012. FANCB GENE; FANCB. [online]. Available at: http://omim.org/allelicVariant/300515
Paugh, S. W., Stocco, G., and Evans, W. E., 2010. Pharmacogenomics in Pediatric Leukemia. Current Opinion in Pediatric, 22(6), pp. 703-710
UCSF Medical Center, 2008. Standardized Procedure: Bone Marrow Aspiration. [online]. Available at: <http://www.ucsfmedicalcenter.org/medstaffoffice/Standardized_Procedures/Bone%20Marrow%20Aspiration.pdf>
Walko, C. M. and Ikediobi, O., 2012. Pharmacogenomic Applications in Oncology, J Pharm Pract, 25(4), pp. 439-446.
Please type your essay title, choose your document type, enter your email and we send you essay samples